Initial Therapeutics, Inc. — Form D/A
Initial Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D amendment with the SEC on 2021-02-04. The offering totals $75.0M, of which $3.8M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-02-04
- Form: D/A
- Accession: 0001816514-21-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $75.0M
- Amount sold: $3.8M
- Remaining: $71.2M
- Investors: 1
- Date of first sale: 2020-07-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-371190
Issuer
- Name: Initial Therapeutics, Inc.
- CIK: 0001816514
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 230 PARK AVENUE, SUITE 2800, NEW YORK, NY, 10169
- Phone: 781-367-5419
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Rajesh H Chopra | Director | New York, NY |
| James H Doudna Cate | Director | New York, NY |
| Michael Ehlers | Director | Morristown, NJ |
| Seth Harrison | Director | Redwood City, CA |
| Spiros Liras | Director | New York, NY |
| Spiros Liras | Executive Officer | New York, NY |
Other filings by this issuer (1)
More